Kathy Sapp, CEO of The American Chronic Pain Association, a philanthropic organization, and Dr. David Armstrong, podiatric surgeon, and researcher with Keck School of Medicine at the University of Southern California discuss nerve damage caused by diabetes called diabetic peripheral neuropathy (DPN) or diabetic nerve pain as it is most commonly called. They also talk about an educational campaign called “Name That Pain” launched by Averitas Pharma, the American Chronic Pain Association, and members of the medical and patient community to raise awareness and emphasize the importance of identifying symptoms of diabetic nerve pain and talking with a healthcare provider early in the treatment journey.
Dr. Rakesh Jain, Clinical Professor, Department of Psychiatry, Texas Tech School of Medicine, Austin, TX discusses tardive dyskinesia or TD, a chronic condition characterized by uncontrollable body movements that can occur in one or more areas of the body. TD is associated with taking certain mental health medications.
Miki Rossanis, Head of Clinical Development at Sensi.AI, based in Tel Aviv, discusses the world’s first AI-powered in-home virtual care agent. Sensi’s technology takes on the growing challenges in long term care by providing data that helps in extending the limited human workforce that takes care of our older adults. Rather than aiming to replace human, high touch care, Sensi enables care providers to optimize their service, and provides a layer of support when there is no in-home human care present. Sensi’s technology provides predictive analytics of behaviors as well as cognitive and physical changes, identifying risk factors before they materialize and cause irreversible damage. Sensi is an invaluable tool in mitigating risk, aiding in early detection of conditions, and understanding and supporting the home environment and its myriad challenges for care.
Returning guest, Lloyd Miller, MD, PhD, Vice President, Immunodermatology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC discusses new data showing TREMFYA ® (guselkumab) provides safe and durable skin clearance through five years in moderate to severe plaque psoriasis (PsO), regardless of baseline disease characteristics or metabolic comorbidities, and meaningful clinical improvements in sexual dysfunction, social relationship dysfunction, and fatigue. These data were presented at the Academy of Dermatology (AAD) annual meeting 2022.
Angela Mickalide, PhD, MCHES, Vice President, Programs & Education, American College of Preventive Medicine discusses her involvement in the Vaccine Confident Campaign, which addresses the rampant misinformation that led to fear and hesitation regarding the COVID-19 vaccine and a dramatic decline in routine vaccinations nationwide, and that is currently being presented at the 2022 Art & Science of Health Promotion Conference.
Dennis Urbaniak, Executive Vice President of Digital Therapeutics at Orexo, a pharmaceutical and digital therapeutics company that addresses the unmet needs in the mental health and substance use space, discusses Deprexis ®, a fully automated digital therapy to help manage symptoms of chronic or recurrent depression or depressive disorders for patients aged 18 and older. Deprexis ®, which is supported by artificial intelligence to tailor delivery based on patients’ progress and specific needs, is software that successfully provides cognitive behavioral therapy (CBT)-based content and other effective psychotherapeutic-based techniques against depression.
Irwin Stromeyer, Owner, Sterile Space Infection Defence, LLC, discusses biopreparedness, the current ‘twin-demic’ of COVID and FLU or ‘Flurona’, and strategies on how to protect oneself from getting these viruses.
Dr. Amy Peterson, MD, President and Chief Operating Officer at CytomX Therapeutics, Inc. discusses its Probody ® therapeutic platform and pipeline to destroy cancer, differently – designing biologic therapies to preferentially engage and kills cancer cells, not healthy cells, thanks to an ingenious gatekeeping mechanism that masks a therapeutic’s binding site until it is conditionally activated and removed by conditions common to the tumor microenvironment. She also talks about the company’s clinical-stage research programs and their leadership in the growing space of conditional activation therapy in oncology.
In this interview, Dr. Vivek Shah, MD, Director of Outpatient Arthroplasty in the Department of Orthopedics and a member of the faculty at Harvard Medical School talks about his recent research ”Clinical Outcomes and Survivorship of Distal Femur Replacements Using Cemented versus Cementless Femoral Stems” and ”Optimizing Spinal Anesthesia Formulation In Same Day Discharge Total Joint Arthroplasty Patients: Mepivacaine vs Ropivacaine” which was recently presented at the 2022 American Academy of Orthopaedic Surgeons Annual meeting.
Jennifer Lewey, M.D., MPH, and Go Red for Women volunteer talks about how nearly 45% of women in their twenties and up are living with some form of cardiovascular disease and less than half of U.S. women have good heart health as they enter pregnancy. In fact, pregnancy-related deaths in the U.S. are rising at an alarming rate, and racial and ethnic disparities in pregnancy-related mortality are significant. It’s vital that women are healthy before, during, and after their pregnancy, as improved heart health before pregnancy can reduce their medical risks later. The American Heart Association is implementing the second year of the Millions Honoring Moms campaign, recognizing the role that moms play in our lives by raising critical funds all throughout May.
Starting May 1, every online donation to the American Heart Association and American Stroke Association will be matched up to $500,000 thanks to the generosity of Valerie and Lee Shapiro. Donors will also be able to send a digital card to a special mom in their life letting them know a special donation was made in their name. #MomsAreWhy
Please direct to www.GoRedforWomen.org/Moms for the donate link.